Innova Captab Reports Robust FY26 Growth, Invests in New Jammu Facility

Innova Captab's Revenue from Operations reached ₹1,630.02 crore in FY 2026, a 31.1% increase year-on-year. Profit After Tax (PAT) grew 9.9% to ₹140.92 crore.

Reader Takeaway: Strong revenue growth driven by generics; new facility ramp-up impacts margins short-term.

What just happened

Innova Captab announced its financial results for FY 2026, showcasing significant top-line growth. Revenue from operations surged by 31.1% to ₹1,630.02 crore compared to ₹1,243.68 crore in FY 2025. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) increased by 26.3% to ₹250.34 crore.

Profit After Tax (PAT) saw a 9.9% rise, reaching ₹140.92 crore from ₹128.26 crore in the previous fiscal. The company also declared a dividend of ₹2 per equity share.

Why this matters

This strong performance indicates healthy demand and successful business operations. The significant revenue jump, especially in the Branded Generics segment, signals market traction. The dividend payout reflects confidence in sustained profitability.

The backstory

The company has invested in a new manufacturing facility in Kathua, Jammu, which is crucial for its future expansion plans. This facility is expected to enhance operating leverage as it reaches higher capacity utilization. The investment is also eligible for GST-linked incentives and capital interest subventions.

What changes now

With the new facility in Kathua coming online, Innova Captab is positioned for future growth. While the initial ramp-up involves fixed costs that have affected margins, increased capacity utilization is anticipated to improve profitability over time. The company's performance in the Branded Generics segment, which grew 51.4% year-on-year, is a key driver.

Risks to watch

Potential supply chain disruptions due to geopolitical tensions in the Middle East are noted as an external risk. Additionally, the fixed costs associated with ramping up the new Kathua facility could continue to exert some pressure on margins in the short term.

Peer comparison

While specific peer financial data for FY26 is not provided in the filing, Innova Captab's focus on both Contract Development and Manufacturing Organization (CDMO) services and Branded Generics places it within the broader Indian pharmaceutical sector, which is known for its competitive landscape.

Context metrics (time-bound)

• FY 2026 Revenue: ₹1,630.02 crore (up 31.1% YoY)
• FY 2026 EBITDA: ₹250.34 crore (up 26.3% YoY)
• FY 2026 PAT: ₹140.92 crore (up 9.9% YoY)
• CDMO Revenue (FY26): ₹1,133.35 crore
• Branded Generics Revenue (FY26): ₹496.67 crore (up 51.4% YoY)
• Dividend: ₹2 per equity share

What to track next

Investors will be keen to monitor the capacity utilization progress at the new Kathua facility and its impact on margins. Tracking the continued growth momentum in the Branded Generics segment and the company's ability to navigate potential global supply chain volatilities will be crucial.